Skip to main content

Table 1 Patient-reported outcomes measurements and meaningful values

From: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

PRO

Range

MCID

Normative value

PtGA

0–100 mm

≥−10 mm [18, 24, 25]

≤20 [ (40)]

Pain (VAS)

0–100 mm

≥−10 mm [24, 25]

 

HAQ-DI

0–3

≥−0.22 units [24, 25]

≤0.25 unit [41]

Morning stiffness

 Duration

Duration in minutes

½ baseline mean STD

 

 Severity

0–10

≥−1 point

 

SF-36

 SF–36 PF

0–100

≥5.0 points [24]

77.25a

 SF–36 RP

0–100

78.19a

 SF–36 BP

0–100

67.60a

 SF–36 GH

0–100

69.08a

 SF–36 VT

0–100

57.11a

 SF–36 SF

0–100

83.37a

 SF–36 RE

0–100

86.07a

 SF–36 MH

0–100

75.61a

 PCS/MCS

0–100

≥2.5 points [24, 25]

≥50 points [24, 25]

FACIT-F

0–52

≥4.0 points [25]

≥43.6 points [42]

EQ-5D-5L

Index scoreb

≥0.05 points [43]

≥0.92 points [44]

WPAI

0 – 100%

≥7% reduction [18]

 
  1. aNormative values for SF-36 domains are based on an aged and gender matched population. bThe EQ-5D-5L is an index score wherein each section is rated from 1 to 5 and then scores indexed to a value ≤1. A score of 1 would indicate best health state. BP bodily pain, EQ-5D-5L EQ-5D 5-Level, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, GH general health, HAQ-DI Health Assessment Questionnaire Disability Index, MCID minimal clinically important difference, MCS Mental Component Summary, MH mental health, PCS Physical Component Summary, PF physical functioning, PtGA Patient Global Assessment of Disease Activity, RE role emotional, RP role physical, SF social functioning, SF-36 36-Item Short Form Health Survey, VAS visual analog scale, VT vitality, WPAI Work Productivity and Activity Impairment